📰 Scott Struthers News
Page 4 - Scott Struthers News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Scott Struthers. Real-time updates on events, politics, business and more.
September 11, 2023
Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) had its price target upped by Evercore ISI from $41.00 to $48.00 in a research report issued to clients and investors on Monday, FlyOnTheWall reports. Evercore ISI’s target price would indicate a potential upside of 200.56% from the company’s previous close. A number of other research firms also […]
September 11, 2023
Crinetics announced findings from the PATHFNDR-1 trial showing the investigative oral daily drug may provide patients with the rare disease an alternative from recurring injection therapy.
September 10, 2023
If approved by the FDA, Paltusotine would be the company's first drug on the market. It treats a rare disorder caused by a tumor on a person's pituitary gland that causes the release of too much growth hormone.
September 3, 2023
Oppenheimer initiated coverage on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) in a research note issued to investors on Wednesday, MarketBeat.com reports. The brokerage issued an outperform rating and a $40.00 price objective on the stock. A number of other research firms have also recently issued reports on CRNX. Robert W. Baird reduced their […]
August 11, 2023
Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its price target cut by HC Wainwright from $35.00 to $33.00 in a research note released on Wednesday morning, MarketBeat Ratings reports. The firm currently has a buy rating on the stock. A number of other equities analysts also recently commented on CRNX. JMP Securities boosted their price […]
June 26, 2023
Bourgeon Capital Management LLC raised its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating) by 56.6% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,150 shares of the company’s stock after buying an additional 1,500 shares during the quarter. […]
June 24, 2023
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating) CEO Richard Scott Struthers sold 50,000 shares of the business’s stock in a transaction dated Friday, June 16th. The stock was sold at an average price of $20.81, for a total transaction of $1,040,500.00. Following the sale, the chief executive officer now owns 680,805 shares in the company, […]
June 22, 2023
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating)’s share price traded down 5.5% during trading on Thursday following insider selling activity. The company traded as low as $18.58 and last traded at $18.62. 204,711 shares changed hands during mid-day trading, a decline of 54% from the average session volume of 444,003 shares. The stock had previously […]
June 21, 2023
Early-Stage Candidates for Primary Hyperparathyroidism and Thyroid Eye Disease Also Featured Crinetics Founder & CEO, Scott Struthers Accepted John D. Baxter Prize for Entrepreneurship from... | June 21, 2023
June 21, 2023
In the TRAVERSE trial, men with hypogonadism at high risk for CVD who received testosterone had a similar risk for major adverse cardiovascular events compared with those who received placebo. A. Michael Lincoff, MD, vice chair for research, cardiovascular medicine and professor of medicine at Cleveland Clinic, said during a presentation at ENDO 2023 that the findings “should